Accenture plc (ACNB34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 1,254.93 |
|---|---|
| 52-week range | 609.00 – 1,564.20 |
| Return, 1 month / 3 months | +37.3% / +58.4% |
| Return, 1 year / 3 years | −3.4% / −9.5% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 55.2% |
| Worst drawdown (1 year) | -59.2% |
| Average daily value traded | 0.10M BRL |
| Dividend yield | 7.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Accenture is a professional services company that advises organisations on strategy, technology and operations, and runs large parts of their day-to-day work for them. Its consultants help clients with digital transformation, cloud computing, systems integration and business process outsourcing. Customers include businesses and government bodies across many industries, such as banking, health, communications and consumer goods. The company is incorporated in Ireland and maintains its headquarters in Dublin, with staff and offices in many countries around the world.
Accenture plc is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code ACNB34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Accenture plc (ACNB34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 1,254.93 on 27 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 713 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.4% and over the last three months it rose 58.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 28.0% | ||
| From 52-week high | -19.3% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 58.4% | ||
| 6-month return | 42.0% | ||
| 12-month return, skipping the last month | -29.7% | ||
| Stability (higher is calmer) | 17 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 55.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.2% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.10M BRL | ||
| Zero-volume days | 10.0% | ||
| Income | 51 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 7.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.6% |
|---|---|
| 1 month | +37.3% |
| 3 months | +58.4% |
| 6 months | +42.0% |
| 1 year | −3.4% |
| 3 years | −9.5% |
| 5 years | −31.4% |
Signals
| 50-day / 200-day average | 1,013.97 / 980.17 |
|---|---|
| Golden / death cross (60 days) | Golden, 4 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 54.28 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Jul 2026 | EUR 5.9931 |
| 8 Apr 2026 | EUR 5.8288 |
| 12 Jan 2026 | EUR 6.0214 |
| 9 Oct 2025 | EUR 6.1259 |
| 9 Jul 2025 | EUR 5.6591 |
| 9 Apr 2025 | EUR 5.9011 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.